EPO-Mimetic Peptide Pegmolesatide Therapy for Pure Red Cell Aplasia in a Patient with Non-dialysis-dependent Type 1 Diabetic Nephropathy: A Case Report
Pure red cell aplasia (PRCA) is a rare complication of erythropoietin (EPO) therapy, characterized by a severe deficiency in red blood cell production. There is no guideline on the treatment for PRCA because there have been too few cases to perform prospective cohort studies. The main treatments for...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Kidney Medicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590059524001584 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841545945920045056 |
|---|---|
| author | Qiong Chen Xuan Liu Juan Wang Man Yang Qiu-ling Fan |
| author_facet | Qiong Chen Xuan Liu Juan Wang Man Yang Qiu-ling Fan |
| author_sort | Qiong Chen |
| collection | DOAJ |
| description | Pure red cell aplasia (PRCA) is a rare complication of erythropoietin (EPO) therapy, characterized by a severe deficiency in red blood cell production. There is no guideline on the treatment for PRCA because there have been too few cases to perform prospective cohort studies. The main treatments for PRCA include immediate cessation of EPO, restrictive transfusion, and immunosuppressive therapies. A 35-year-old male patient with type 1 diabetic nephropathy was diagnosed with PRCA. Enarodustat and roxadustat were administered successively after discontinuation of EPO, but anemia did not improve, and the patient was maintained with weekly blood transfusions. Subsequently, the EPO-mimetic peptide pegmolesatide was administered, and the patient’s hemoglobin started to increase after 1 week and increased from 50 g/L to 92 g/L over approximately 3 months. Based on these findings, we speculate that pegmolesatide can provide a safe, effective, and convenient therapeutic strategy for PRCA in Chinese patients with chronic kidney disease. |
| format | Article |
| id | doaj-art-e6c716eb7c814f55befca61feac18a0a |
| institution | Kabale University |
| issn | 2590-0595 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Kidney Medicine |
| spelling | doaj-art-e6c716eb7c814f55befca61feac18a0a2025-01-11T06:41:53ZengElsevierKidney Medicine2590-05952025-02-0172100947EPO-Mimetic Peptide Pegmolesatide Therapy for Pure Red Cell Aplasia in a Patient with Non-dialysis-dependent Type 1 Diabetic Nephropathy: A Case ReportQiong Chen0Xuan Liu1Juan Wang2Man Yang3Qiu-ling Fan4Department of Nephrology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Nephrology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Nephrology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Nephrology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Nephrology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Address for Correspondence: Qiu-ling Fan, MD, PhD, Department of Nephrology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 100 Haining Road, Shanghai 200080, China.Pure red cell aplasia (PRCA) is a rare complication of erythropoietin (EPO) therapy, characterized by a severe deficiency in red blood cell production. There is no guideline on the treatment for PRCA because there have been too few cases to perform prospective cohort studies. The main treatments for PRCA include immediate cessation of EPO, restrictive transfusion, and immunosuppressive therapies. A 35-year-old male patient with type 1 diabetic nephropathy was diagnosed with PRCA. Enarodustat and roxadustat were administered successively after discontinuation of EPO, but anemia did not improve, and the patient was maintained with weekly blood transfusions. Subsequently, the EPO-mimetic peptide pegmolesatide was administered, and the patient’s hemoglobin started to increase after 1 week and increased from 50 g/L to 92 g/L over approximately 3 months. Based on these findings, we speculate that pegmolesatide can provide a safe, effective, and convenient therapeutic strategy for PRCA in Chinese patients with chronic kidney disease.http://www.sciencedirect.com/science/article/pii/S2590059524001584Non-dialysis-dependent chronic kidney diseasepegmolesatidepure red cell aplasia |
| spellingShingle | Qiong Chen Xuan Liu Juan Wang Man Yang Qiu-ling Fan EPO-Mimetic Peptide Pegmolesatide Therapy for Pure Red Cell Aplasia in a Patient with Non-dialysis-dependent Type 1 Diabetic Nephropathy: A Case Report Kidney Medicine Non-dialysis-dependent chronic kidney disease pegmolesatide pure red cell aplasia |
| title | EPO-Mimetic Peptide Pegmolesatide Therapy for Pure Red Cell Aplasia in a Patient with Non-dialysis-dependent Type 1 Diabetic Nephropathy: A Case Report |
| title_full | EPO-Mimetic Peptide Pegmolesatide Therapy for Pure Red Cell Aplasia in a Patient with Non-dialysis-dependent Type 1 Diabetic Nephropathy: A Case Report |
| title_fullStr | EPO-Mimetic Peptide Pegmolesatide Therapy for Pure Red Cell Aplasia in a Patient with Non-dialysis-dependent Type 1 Diabetic Nephropathy: A Case Report |
| title_full_unstemmed | EPO-Mimetic Peptide Pegmolesatide Therapy for Pure Red Cell Aplasia in a Patient with Non-dialysis-dependent Type 1 Diabetic Nephropathy: A Case Report |
| title_short | EPO-Mimetic Peptide Pegmolesatide Therapy for Pure Red Cell Aplasia in a Patient with Non-dialysis-dependent Type 1 Diabetic Nephropathy: A Case Report |
| title_sort | epo mimetic peptide pegmolesatide therapy for pure red cell aplasia in a patient with non dialysis dependent type 1 diabetic nephropathy a case report |
| topic | Non-dialysis-dependent chronic kidney disease pegmolesatide pure red cell aplasia |
| url | http://www.sciencedirect.com/science/article/pii/S2590059524001584 |
| work_keys_str_mv | AT qiongchen epomimeticpeptidepegmolesatidetherapyforpureredcellaplasiainapatientwithnondialysisdependenttype1diabeticnephropathyacasereport AT xuanliu epomimeticpeptidepegmolesatidetherapyforpureredcellaplasiainapatientwithnondialysisdependenttype1diabeticnephropathyacasereport AT juanwang epomimeticpeptidepegmolesatidetherapyforpureredcellaplasiainapatientwithnondialysisdependenttype1diabeticnephropathyacasereport AT manyang epomimeticpeptidepegmolesatidetherapyforpureredcellaplasiainapatientwithnondialysisdependenttype1diabeticnephropathyacasereport AT qiulingfan epomimeticpeptidepegmolesatidetherapyforpureredcellaplasiainapatientwithnondialysisdependenttype1diabeticnephropathyacasereport |